# O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

> **NCT00003613** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** O6-benzylguanine
- **DRUG:** carmustine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00003613
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-04
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2013-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003613, "O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*